Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain.

Lamason RL, McCully RR, Lew SM, Pomerantz JL.

Biochemistry. 2010 Sep 28;49(38):8240-50. doi: 10.1021/bi101052d.

2.

Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.

Fontán L, Melnick A.

Clin Cancer Res. 2013 Dec 15;19(24):6662-8. doi: 10.1158/1078-0432.CCR-12-3869. Epub 2013 Sep 4. Review.

3.

NF-kappaB signaling in lymphocytes: a new cast of characters.

Lucas PC, McAllister-Lucas LM, Nunez G.

J Cell Sci. 2004 Jan 1;117(Pt 1):31-9. Review.

4.

The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency.

Turvey SE, Durandy A, Fischer A, Fung SY, Geha RS, Gewies A, Giese T, Greil J, Keller B, McKinnon ML, Neven B, Rozmus J, Ruland J, Snow AL, Stepensky P, Warnatz K.

J Allergy Clin Immunol. 2014 Aug;134(2):276-84. doi: 10.1016/j.jaci.2014.06.015. Review.

5.

Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.

Knittel G, Liedgens P, Korovkina D, Pallasch CP, Reinhardt HC.

Eur J Haematol. 2016 Dec;97(6):499-510. doi: 10.1111/ejh.12792. Epub 2016 Sep 8. Review.

PMID:
27526684
6.

The CBM signalosome: potential therapeutic target for aggressive lymphoma?

Yang C, David L, Qiao Q, Damko E, Wu H.

Cytokine Growth Factor Rev. 2014 Apr;25(2):175-83. doi: 10.1016/j.cytogfr.2013.12.008. Epub 2013 Dec 24. Review.

7.

Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity.

Pérez de Diego R, Sánchez-Ramón S, López-Collazo E, Martínez-Barricarte R, Cubillos-Zapata C, Ferreira Cerdán A, Casanova JL, Puel A.

J Allergy Clin Immunol. 2015 Nov;136(5):1139-49. doi: 10.1016/j.jaci.2015.06.031. Epub 2015 Aug 12. Review.

8.

B-cell receptor signaling as a driver of lymphoma development and evolution.

Niemann CU, Wiestner A.

Semin Cancer Biol. 2013 Dec;23(6):410-21. doi: 10.1016/j.semcancer.2013.09.001. Epub 2013 Sep 20. Review.

9.

Determining the destiny of NF-kappa B after TCR ligation: it's CARMA1.

Bunnell SC.

Mol Interv. 2002 Oct;2(6):356-60, 338. Review.

PMID:
14993411
10.

Oncogenic activation of NF-kappaB.

Staudt LM.

Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000109. doi: 10.1101/cshperspect.a000109. Epub 2010 Apr 21. Review.

11.

MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.

Afonina IS, Elton L, Carpentier I, Beyaert R.

FEBS J. 2015 Sep;282(17):3286-97. doi: 10.1111/febs.13325. Epub 2015 Jun 10. Review.

12.

The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling.

Lin X, Wang D.

Semin Immunol. 2004 Dec;16(6):429-35. Review.

PMID:
15541657
13.

Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.

Lim KH, Yang Y, Staudt LM.

Immunol Rev. 2012 Mar;246(1):359-78. doi: 10.1111/j.1600-065X.2012.01105.x. Review.

14.

Antigen-receptor signaling to nuclear factor kappa B.

Schulze-Luehrmann J, Ghosh S.

Immunity. 2006 Nov;25(5):701-15. Review.

15.

B-cell receptor signaling in diffuse large B-cell lymphoma.

Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM.

Semin Hematol. 2015 Apr;52(2):77-85. doi: 10.1053/j.seminhematol.2015.01.008. Epub 2015 Jan 15. Review.

16.

Scaffolding of antigen receptors for immunogenic versus tolerogenic signaling.

Jun JE, Goodnow CC.

Nat Immunol. 2003 Nov;4(11):1057-64. Review.

PMID:
14586424
17.

Regulation of NF-κB by the CARD proteins.

Jiang C, Lin X.

Immunol Rev. 2012 Mar;246(1):141-53. doi: 10.1111/j.1600-065X.2012.01110.x. Review.

18.

Signaling in lymphocyte activation.

Cantrell D.

Cold Spring Harb Perspect Biol. 2015 Jun 1;7(6). pii: a018788. doi: 10.1101/cshperspect.a018788. Review.

PMID:
26032717

Supplemental Content

Support Center